Related Experiment Video
Updated: Apr 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm
Shannon W Finks1, Jennifer D Campbell
1Shannon W. Finks is an associate professor at the University of Tennessee, College of Pharmacy, Memphis, Tenn. Jennifer D. Campbell is a Clinical Pharmacist of Ambulatory Care at Regional Medical Center, Memphis, Tenn.
Abstract:
Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Drug Toxicity: Risk factors

